Home > Oncology > WCLC 2022 > WCLC 2022 Congress Round-Up > Talazoparib plus temozolomide appears efficacious in ES-SCLC

Talazoparib plus temozolomide appears efficacious in ES-SCLC

Presented By
Dr Jonathan Goldman, David Geffen School of Medicine at UCLA, CA, USA
Conference
WCLC 2022
Trial
Phase 2
Doi
https://doi.org/10.55788/236b8e48
The combination of talazoparib plus temozolomide reached the primary efficacy endpoint in a phase 2 study that tested this combination therapy in patients with extensive-stage small cell lung cancer (ES-SCLC). Since the safety profile was manageable, a phase 3 study is appropriate to confirm the clinical benefits of this treatment [1]. The current phase 2 trial (NCT03672773) evaluated the efficacy of the PARP inhibitor talazoparib in combination with temozolomide in 28 patients with relapsed or refractory ES-SCLC. Dr Jonathan Goldman (David Geffen School of Medicine at UCLA, CA, USA) presented the findings. An objective response rate (ORR) of 29% was needed to meet the primary endpoint. The ORR was 39.3%, representing 11 patients with partial responses. The median time to response was 1.8 months, and the median duration of response was 4.3 months. In additio...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on